Narendranath Epperla, MD, MS is currently an Associate Professor at The Huntsman Cancer Institute, University of Utah, Division of Hematology and Hematologic Malignancies. After receiving his medical degree in India, Dr. Epperla came to the U.S. and completed his Internal Medicine Residency at Marshfield Clinic where he also served as a Chief Resident. He obtained his master’s degree in Clinical and Translational Science and completed a fellowship in Hematology/Oncology at the Medical College of Wisconsin. He received several awards during this fellowship and as a junior faculty from ASH, ASCO, and ASTCT. He joined The Ohio State University in 2017 as Assistant Professor in the Lymphoma program. 

Dr. Epperla is actively involved in cancer research. His research interests focus on conducting early-phase clinical trials using novel drug combinations to treat patients with lymphoid malignancies, develop post-CAR-T relapse mitigation strategies, as well as to identify blood-based biomarkers that can predict treatment response. In addition to working on investigator-initiated trials, he is working on several industry sponsored and cooperative group trials in lymphomas and cellular therapy realm.

Dr. Epperla is a member of several professional organizations, including the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplantation and Cellular Therapy, and the American Association for Cancer Research. He is actively involved in the CIBMTR lymphoma committee and has published several high-impact papers utilizing the registry. He has moderated sessions at ASH over the past few years and has authored over 150 peer-reviewed publications. He is on the editorial boards of Frontiers in Oncology, Frontiers in Immunology, BMC Medicine, and Journal of Hematology and Oncology. Dr. Epperla is a reviewer for several reputable medical journals, including NEJM, Blood, JAMA Oncology, JAMA Network Open, Blood Advances among others, and has reviewed over 300 papers for high-impact journals in the past 4 years.